Table 1. Key study features.
| Study | Year | Patients | Bioprosthetic valve (%) | Operative time | Country | Multicentre (n) | Follow-up<§ (years) |
|---|---|---|---|---|---|---|---|
| Sanfelippo et al | 1976 | 15 | 0 (0) | Up to 1972 | USA | No | 4 |
| Glower et al* | 1995 | 35 | 35 (100) | 1974-1993 | USA | No | In-hospital |
| Ian Munro et al | 1995 | 30 | NR | 1975-1992 | Canada | No | 4 |
| Do et al | 2000 | 29 | 26 (90) | 1978-1998 | Canada | No | 6 |
| Mangoni et al | 2001 | 15 | 5 (33) | 1984-1994 | USA | No | 3 |
| Maleszka et al | 2004 | 20 | 5 (25) | 1985-2002 | Germany | No | 3 |
| Solomon et al | 2004 | 33 | 25 (76) | 1996-2002 | N. Zealand | No | 5 |
| Iscan et al | 2007 | 20 | NR | 1987-2004 | Turkey | No | 6 |
| Tokunaga et al* | 2008 | 31 | 27 (87) | 1975-2004 | Japan | No | 8 |
| Capoun et al | 2010 | 11 | 8 (73) | 1999-2009 | UK | No | 2 |
| Baraki et al* | 2013 | 18 | 14 (78) | 1996-2012 | Germany | No | 6 |
| Kim et al* | 2013 | 14 | 10 (71) | 1996-2010 | Republic of Korea | No | 3 |
| Bevan et al | 2014 | 29 | 23 (79) | 1995-2011 | N. Zealand | No | 14 |
| Buzzatti et al | 2014 | 61 | NR | 1997-2012 | Italy | No | 5 |
| Farag et al | 2017 | 68 | 36 (53) | 1995-2011 | Germany | No | NR |
| Hanedan et al* | 2017 | 30 | 10 (33) | 2004-2011 | Turkey | No | 2 |
| Rossello et al | 2017 | 25 | 0 (0) | 1996-2012 | Spain | No | 5 |
| Çakıcı et al | 2018 | 25 | 22 (88) | 2010-2016 | Turkey | No | 2 |
| Chen et al* | 2018 | 118 | 102 (86) | 2003-2016 | China | No | In-hospital |
| Fang et al* | 2018 | 90 | 74 (82) | 2007-2016 | China | No | 9 |
| Moutakiallah et al | 2018 | 11 | 5 (45) | 2000-2017 | Morocco | No | 6 |
| Di Mauro et al | 2019 | 80 | 54 (68) | 1979-2018 | Italy | Yes (21) | 19 |
| Kundi et al* | 2019 | 2,670 | 1,737 (65) | 2003-2014 | USA | Yes (841) | 1 |
| Liang et al* | 2019 | 76 | 43 (57) | 2010-2017 | China | No | 4 |
| Chen et al* | 2020 | 107 | 25 (23) | 2009-2017 | China | No | 5 |
| Dreyfus et al | 2020 | 273 | 264 (97) | 2007-2017 | France | Yes (12) | 3 |
| Sánchez-EspÃn G et al* | 2020 | 56 | 48 (86) | 1996-2017 | Spain | No | 4 |
| Wong et al | 2020 | 137 | NR | 2000-2013 | Taiwan | Yes (NA) | 4 |
| Yan et al* | 2020 | 49 | 49 (100) | 2012-2019 | China | No | 2 |
| Kawsara et al* | 2021 | 552 | 468 (85) | 2016-2017 | USA | Yes (NA) | In-hospital |
| Lee et al | 2021 | 216 | NR | 2000-2013 | Taiwan | Yes (NA) | 4 |
| Leviner et al | 2021 | 33 | 31 (94) | 2007-2018 | Israel | Yes (2) | 4 |
| Liu et al* | 2021 | 186 | 145 (78) | 1999-2018 | China | Yes (2) | 11 |
| Park et al | 2021 | 106 | 23 (22) | 1996-2018 | Republic of Korea | No | 4 |
| Tafti et al# | 2021 | 47 | 41 (87) | 2010-2018 | Iran | No | 5 |
| §Mean follow-up. *Studies reporting outcome data for bioprosthetic valve group. #Reported data were clarified and confirmed upon contacting corresponding authors. NA: not applicable; NR: not reported | |||||||